Study suggests peimine may be a potent inhibitor of SARS-CoV-2 variant infection SARSCoV2 COVID19 coronavirus inhibitor infection
By Shanet Susan AlexAug 2 2022Reviewed by Danielle Ellis, B.Sc. A recent study published in the Journal of Food Biochemistry discovered that peimine from Fritillaria might be a possible severe acute respiratory syndrome coronavirus 2 variant infection inhibitor.
About the study In the present work, to quickly translate bench discoveries to clinical settings, the authors examined whether unbiased drug evaluation on pure compounds from a collection of known herbal plants can uncover prospective anti-SARS-CoV-2 medicines. They used a cell-based experiment to test 126 pure compounds from an extensive drug library, the Natural Compound Library, to find the drugs with antiviral infection efficacy against SARS-CoV-2 and its variants.
Results Related StoriesThe study results indicate that a Fritillary species active component harboring anti-inflammatory traits named peimine might be a promising therapeutic agent for managing COVID-19 patients. Peimine also notably reduced the infection of Vero E6 parental and furin-overexpressing cells by 501Y.V2 and B.1.1.7. After peimine therapy, ACE2-overexpressing 239T cells demonstrated excellent efficiency in preventing Vpp variant infection. According to the study's findings, peimine was a potential drug effective against the SARS-CoV-2 501Y.V2 and B.1.1.7 VOCs as well as the WT strain.
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
Ancestral SARS-CoV-2, but not Omicron, replicates less efficiently in primary pediatric nasal epithelial cellsChildren typically experience more mild symptoms of COVID-19 when compared to adults; why is this? This study uses nasal epithelial cells from children and adults to show that the ancestral SARS-CoV-2 and Delta, but not the Omicron variant, replicate less efficiently in pediatric nasal epithelial cells.
Læs mere »
Decoy ACE2 receptors broadly neutralize SARS-CoV-2 variantsDecoy ACE2 receptors broadly neutralize SARS-CoV-2 variants ACE2 Coronavirus Disease COVID SARSCoV2 CellPressNews osaka_univ_e KyotoU_News
Læs mere »
Study indicates that cross-reactive immunity against SARS-CoV-2 N protein was present in Africa prior to the pandemicResearchers assessed the pre-existing cross-protective immune responses against SARS-CoV-2 nucleocapsid protein and spike protein before the COVID-19 pandemic in individuals residing in North and South America, Europe and Africa in vitro and in vivo.
Læs mere »
SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model - Nature CommunicationsMolnupiravir was the first orally available SARS-CoV-2 antiviral approved for outpatient use against SARS-CoV-2, but its efficacy against variants of concern, especially delta, was questioned. Here the authors evaluate molnupiravir against variant of concern in numerous models, including human airway epithelium organoids, ferrets and Roborovski dwarf hamsters.
Læs mere »
The recent progress in investigating the inhibitory impact of nanosponges and antiviral delivery against SARS-CoV-2The recent progress in investigating the inhibitory impact of nanosponges and antiviral delivery against SARS-CoV-2 StanfordMed nanosponge SARSCoV2 COVID19 coronavirus covid antiviral
Læs mere »
Ancestral SARS-CoV-2, but not Omicron, replicates less efficiently in primary pediatric nasal epithelial cellsChildren typically experience more mild symptoms of COVID-19 when compared to adults; why is this? This study uses nasal epithelial cells from children and adults to show that the ancestral SARS-CoV-2 and Delta, but not the Omicron variant, replicate less efficiently in pediatric nasal epithelial cells.
Læs mere »